Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T18:52:04.250Z.
Calculation as of: 2026-10-06T18:52:04.250Z.
Quote observation: 2026-10-06T18:46:31.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f6adff8253f4c85dc5eb0f5c76b7f284768243a99251a0912c87940a98678e1d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Lifeward Ltd.
Market Cap
$10.10M
Price/FCF Ratio
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO |
|---|---|---|
| Lifeward Ltd. (LFWD) | $10.10M | N/A |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.11M | N/A |
| Tvardi Therapeutics, Inc. (TVRD)vs › | $10.23M | N/A |
| Valion Bio, Inc. (VBIO)vs › | $9.88M | N/A |
| Satellos Bioscience Inc. (MSLE)vs › | $10.41M | N/A |
| NeuroOne Medical Technologies Corporation (NMTC)vs › | $9.73M | N/A |
| Senti Biosciences, Inc. (SNTI)vs › | $10.45M | N/A |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.41M | N/A |
| MetaVia Inc. (MTVA)vs › | $9.62M | N/A |
| Polyrizon Ltd. (PLRZ)vs › | $10.37M | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
